BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33438640)

  • 1. Investigations of potent biocompatible metal-organic framework for efficient encapsulation and delivery of Gemcitabine: biodistribution, pharmacokinetic and cytotoxicity study.
    Kush P; Kaur M; Sharma M; Madan J; Kumar P; Deep A; Kim KH
    Biomed Phys Eng Express; 2020 Feb; 6(2):025014. PubMed ID: 33438640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabrication of dopamine conjugated with protein @metal organic framework for targeted drug delivery: A biocompatible pH-Responsive nanocarrier for gemcitabine release on MCF‑7 human breast cancer cells.
    Abd Al-Jabbar S; Atiroğlu V; Hameed RM; Guney Eskiler G; Atiroğlu A; Deveci Ozkan A; Özacar M
    Bioorg Chem; 2022 Jan; 118():105467. PubMed ID: 34781115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
    Kim DH; Guo Y; Zhang Z; Procissi D; Nicolai J; Omary RA; Larson AC
    Adv Healthc Mater; 2014 May; 3(5):714-24. PubMed ID: 24574255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
    Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
    Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient "green" encapsulation of a highly hydrophilic anticancer drug in metal-organic framework nanoparticles.
    Rodriguez-Ruiz V; Maksimenko A; Anand R; Monti S; Agostoni V; Couvreur P; Lampropoulou M; Yannakopoulou K; Gref R
    J Drug Target; 2015; 23(7-8):759-67. PubMed ID: 26453171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy.
    Han H; Valdepérez D; Jin Q; Yang B; Li Z; Wu Y; Pelaz B; Parak WJ; Ji J
    ACS Nano; 2017 Feb; 11(2):1281-1291. PubMed ID: 28071891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer.
    Cosco D; Bulotta A; Ventura M; Celia C; Calimeri T; Perri G; Paolino D; Costa N; Neri P; Tagliaferri P; Tassone P; Fresta M
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1009-20. PubMed ID: 19263052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
    Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
    Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine-loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile.
    Unnam S; Panduragaiah VM; Sidramappa MA; Muddana Eswara BR
    Curr Drug Deliv; 2019; 16(2):111-122. PubMed ID: 30360740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells.
    Patki M; Saraswat A; Bhutkar S; Dukhande V; Patel K
    Exp Cell Res; 2021 Aug; 405(2):112660. PubMed ID: 34048785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
    Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
    Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model.
    Guo P; Ma J; Li S; Guo Z; Adams AL; Gallo JM
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):169-76. PubMed ID: 11561783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
    Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
    Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): In vitro and in vivo.
    Yalcin TE; Ilbasmis-Tamer S; Takka S
    Int J Pharm; 2020 Apr; 580():119246. PubMed ID: 32205141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer.
    Li YJ; Wu JY; Wang JM; Hu XB; Cai JX; Xiang DX
    Acta Biomater; 2020 Jan; 101():519-530. PubMed ID: 31629893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Encapsulation of gemcitabine in RGD-modified nanoliposomes improves breast cancer inhibitory activity.
    Cai W; Geng C; Jiang L; Sun J; Chen B; Zhou Y; Yang B; Lu H
    Pharm Dev Technol; 2020 Jun; 25(5):640-648. PubMed ID: 32028816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
    Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
    BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biocompatible Fe-Based Micropore Metal-Organic Frameworks as Sustained-Release Anticancer Drug Carriers.
    Leng X; Dong X; Wang W; Sai N; Yang C; You L; Huang H; Yin X; Ni J
    Molecules; 2018 Sep; 23(10):. PubMed ID: 30274195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.